Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: i-node who wrote (935823)	5/19/2016 1:25:35 PM
From: bentway	Read Replies (1) \| Respond to of 1576167

There's a lot of waste and greed in our system of care delivery, Dave. It's why we pay more than any other country on Earth. Big pharma, big insurance and big medicine ALL overcharge. A triple whammy. Of the three, I think big pharma and big medicine are the most at fault.

To: i-node who wrote (935823)	5/19/2016 1:33:02 PM
From: Broken_Clock	Read Replies (1) \| Respond to of 1576167

As I pointed out, I have no idea where that graph came from. As I indicated, I have no idea WHAT you posted apparently you don't understand your own postings. Do you understand the difference between what and where? +++++ The increasing cost of private insurance (notably, since the inception of Medicare, if you notice) is a direct result of cost shifts from Medicare to private insurance. Which is what drives the cost of private insurance up since Medicare fees are price controlled. == completely ridiculous assertion. Medicare is for 65+ are you saying private insurance is only for 65+ year olds

To: i-node who wrote (935823)	5/19/2016 2:22:17 PM
From: bentway	Respond to of 1576167

How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes A billion-dollar system in which charitable giving is profitable. Benjamin Elgin Robert Langreth Bloomberg Businessweek bloomberg.com Excerpt: In August 2015, Turing Pharmaceuticals and its then-chief executive, Martin Shkreli, purchased a drug called Daraprim and immediately raised its price more than 5,000 percent. Within days, Turing contacted Patient Services Inc., or PSI, a charity that helps people meet the insurance copayments on costly drugs. Turing wanted PSI to create a fund for patients with toxoplasmosis, a parasitic infection that is most often treated with Daraprim. Having just made Daraprim much more costly, Turing was now offering to make it more affordable. But this is not a feel-good story. It’s a story about why expensive drugs keep getting more expensive, and how U.S. taxpayers support a billion-dollar system in which charitable giving is, in effect, a very profitable form of investing for drug companies—one that may also be tax-deductible...